ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$63.93 USD
+0.58 (0.92%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $63.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIP 63.93 +0.58(0.92%)
Will ANIP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Other News for ANIP
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 ...
ANIP Faces Setback in Legal Dispute Over Royalties
ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value
Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment
ANI Pharmaceuticals (ANIP) Shares Drop Following Clinical Trial Results